GRADALIS

GRADALIS, INC.

24 Investors

Biotechnology - Immunotherapy

Carrollton, TX

Gradalis, Inc. is a clinical-stage biotechnology firm dedicated to developing and commercializing personalized therapeutics, primarily focused on immunotherapy for cancer treatment. Founded in 2006 and headquartered in Carrollton, Texas, the company aims to transform how cancer is treated by harnessing the power of the patient's own immune system.

Products & Team

Vigil – Personalized Cancer Immunotherapy

Cancer ImmunotherapySeed

Vigil is a proprietary immunotherapy platform that treats cancer by activating the patient’s immune system using their own tumor cells. This personalized approach allows for an effective recognition and destruction of cancer cells.

Value Proposition

Vigil addresses the limitations of standard treatments by providing personalized cancer therapies that are tailored to the unique characteristics of each patient's cancer, potentially increasing treatment success rates while minimizing side effects.

Pain Points

Patients face significant challenges with standard cancer treatments, including ineffectiveness of one-size-fits-all therapies, risk of severe side effects, and the need for pain mitigation in advanced disease stages.

Fully personalized therapy based on individual tumor cellsTargets a wide range of tumor antigens, including clonal neoantigensUtilizes bi-shRNA technology to enhance effectivenessCan be administered alone or in combination with other treatments